# US 2019/0241619 A1 · Novel Promiscuous HPV16-Derived T Helper Epitopes for Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241619 A1
- Document ID: US20190241619A1
- Status: Published application
- Kind: A1
- Application number: 16/385,577
- Filed: 2019-04-16
- Published: 2019-08-08
- Earliest claimed: 2013-12-12
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffenttichen Rechts
- Applicants: Deutsches Krebsforschungszentrum Stiftung des Öffenttichen Rechts
- Inventors: Agnieszka Grabowska; Angelika Riemer
- Web page: https://patentgrep.com/patent/US20190241619A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/525: {Virus}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20051: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to novel amino acid sequences of peptides derived from HPV16 that are able to promiscuously bind to MHC complexes of class II and shorter peptides contained in the promiscuously binding peptides that bind to MHC complexes of class I, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and T-cells, based on said epitopes.

## Claims

### Claim 1

A peptide comprising a sequence selected from the group of SEQ ID NO: 7, and SEQ ID NOs: 32 to 42, or a variant of SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, wherein said variant is 80% homologous to SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, and wherein said peptide or parts thereof have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-II and/or class-I, and wherein said peptide has an overall length of between 8 and 50 amino acids.

### Claim 2 (depends on 1)

The peptide or variant thereof according to claim 1, wherein said peptide or variant thereof has a length of between 15 and 30 amino acids for a peptide or variant thereof comprising a sequence according to SEQ ID NO: 7, or wherein said peptide or variant thereof has a length of between 8 and 30 amino acids for a peptide comprising a sequence according to any of SEQ ID NOs: 32 to 42.

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein said peptide consists essentially of an amino acid sequence selected from the group of SEQ ID NO: 7, and SEQ ID NOs: 32 to 42.

### Claim 4 (depends on 1)

The peptide according to claim 1, wherein said peptide has a binding affinity of IC50≤60 nM to a HLA molecule.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the peptide according to claim 1, and optionally at least one additional peptide having an amino acid sequence selected from the group of SEQ ID NOs: 1 to 42.

### Claim 6 (depends on 1)

The peptide according to claim 1, wherein said peptide is part of a fusion molecule.

### Claim 7 (depends on 1)

A nucleic acid encoding the peptide according to claim 1.

### Claim 8 (depends on 7)

An expression vector capable of expressing the nucleic acid according to claim 7.

### Claim 9 (depends on 7)

A host cell comprising the nucleic acid according to claim 7.

### Claim 10 (depends on 1)

A method for producing the peptide according to claim 1, said method comprising synthesizing said peptide; or culturing a host cell and isolating said peptide from said host cell or the culture medium thereof.

### Claim 11 (depends on 1)

A method for producing activated T cells, the method comprising contacting TH cells or CTLs with antigen loaded human class II or I MHC molecules expressed on the surface of antigen-presenting cells for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide according to claim 1.

### Claim 12 (depends on 11)

Activated T cells, produced by the method according to claim 11, which cells selectively recognize cells that express an HPV polypeptide comprising a sequence selected from the group of SEQ ID NO: 7, and SEQ ID NOs: 32 to 42, or a variant of SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, wherein said variant is 80% homologous to SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, and wherein said peptide or parts thereof have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-II and/or class-I.

### Claim 13 (depends on 12)

A pharmaceutical preparation, comprising at least one of:
a) a nucleic acid encoding a sequence selected from the group of SEQ ID NO: 7, and SEQ ID NOs: 32 to 42, or a variant of SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, wherein said variant is 80% homologous to SEQ ID NO: 7, or any of SEQ ID NOs: 32 to 42, and wherein said peptide or parts thereof have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-II and/or class-I, and wherein said peptide has an overall length of between 8 and 50 amino acids;
b) an expression vector or a host cell comprising the nucleic acid of part a); and
c) the activated T cells according to claim 12;
and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 5)

A method for treating HPV infection, HPV-related premalignancies and/or malignancies comprising administering the pharmaceutical composition according to claim 5 to a patient in need of said treatment.

### Claim 15 (depends on 14)

The method for treating HPV infection, HPV-related premalignancies and/or malignancies according to claim 14, wherein said treatment is MHC-I and/or MHC-II peptide presentation dependent.

### Claim 16 (depends on 13)

A method for treating HPV infection, HPV-related premalignancies and/or malignancies comprising administering the pharmaceutical preparation according to claim 13 to a patient in need of said treatment.

### Claim 17 (depends on 16)

The method for treating HPV infection, HPV-related premalignancies and/or malignancies according to claim 16, wherein said treatment is MHC-I and/or MHC-II peptide presentation dependent.

### Claim 18 (depends on 9)

The host cell, according to claim 9, wherein the cell is an antigen presenting cell.
